Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

Diabetes Care

Volumn 33, Issue 6, 2010, Pages 1300-1303

  Buse, John B ^a   Sesti, Giorgio ^b   Schmidt, Wolfgang E ^c   Montanya, Eduard ^d   Chang, Cheng Tao ^e   Xu, Yizhen ^e   Blonde, Lawrence ^f   Rosenstock, Julio ^g  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c ST JOSEF HOSPITAL   (Germany)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e NOVO NORDISK INC   (United States)

^f OCHSNER MEDICAL CENTER   (United States)

^g DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; VENOM;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ADULT; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; BRAIN INFARCTION; CATARACT; CELL FUNCTION; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSED MOOD; DEPRESSION; DIARRHEA; DIET RESTRICTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ERUCTATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LETHARGY; MAJOR CLINICAL STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREATITIS; PARESTHESIA; PORTAL VEIN THROMBOSIS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SIDE EFFECT; STOMACH EMPTYING; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; THYROID MEDULLARY CARCINOMA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; DRUG ADMINISTRATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; VENOMS;

EID: 77956076972     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-2260     Document Type: Article

References (12)

1. Horton ES. Can newer therapies delay the progression of type 2 diabetes mellitus? Endocr Pract 2008;14:625-638
2. Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008;5:73-94
3. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
4. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera- Alvarez I, Hale PM, Zdravkovic M, Bode B, LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, doubleblind, parallel-treatment trial. Lancet 2009;373:473-481
5. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S, LEAD-1 SU Study Group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278
6. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR, LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90
7. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L, LEAD-4 Study Investigators. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-1230
8. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R, Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-2055
9. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635
10. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100 (Pubitemid 40616618)
11. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091 (Pubitemid 40616617)
12. Rosenstock J, Gumprecht J, Szyprowska E, Bednarczyk-Kaluzny M, Zychma M, During M, Buse J: Pharmacokinetics of liraglutide vs. exenatide in type 2 diabetes: sustained vs. fluctuating concentrations over 24 hours (LEAD-6) (Abstract). Diabetes 2009;58(Suppl. 1):A150